Tuvatexib Drug Asset Due Diligence Report 2026

This Tuvatexib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Tuvatexib can convert its Small molecule drug profile and HK2 x VDAC1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tuvatexib (query alias: Tuvatexib)
Modality / target	Small molecule drug; HK2 x VDAC1; HK2 modulators, VDAC1 modulators
Highest global status	Phase 2
Originator	Vidac Pharma Ltd.
Active developers	Vidac Pharma Ltd.

The MCP disease footprint includes Actinic Keratosis, Cutaneous T-Cell Lymphoma, Brain Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT03538951	Phase 2	Completed	83	Primary endpoint not disclosed in English source
NCT02844777	Phase 2	Completed	93	Primary endpoint not disclosed in English source
CTIS2025-522482-30-00	Phase 2	Ongoing, recruitment ended	39	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Vidac Pharma Reports Exceptional Pharmacokinetics of Almavid™ Drug Candidate in Real-World Clinical study

Not Applicable; n=3; evaluation: Positive. Reported fields: PK = Administered to three pediatric patients with brain cancer, Almavid™ demonstrated exceptional pharmacokinetic properties, including high blood stability for over 24 hours, strong dose linearity, and sustained blood concentration levels across patients. These findings suggest that Almavid™ has strong potential as a broad-spectrum treatment for solid tumors, both as a monotherapy and in combination therapies.

Randomized, Double-Blind, Placebo-Controlled, Parallel-Cohort Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Once-Daily Application of Topical VDA-1102 Ointment for 28 Days in Subjects With Actinic Keratosis

Phase 2; n=93; evaluation: Not stated in English source. Reported fields: Change From Baseline in the Number of Actinic Keratosis Lesions in the Treatment Field on Day 56(Mean) = -1.54 Lesion ; Change From Baseline in the Number of Actinic Keratosis Lesions in the Treatment Field on Day 56(Mean) = -1.34 Lesion

Phase 2B Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis

Phase 2; n=83; evaluation: Not stated in English source. Reported fields: Complete Clearance Rate = 7 Pts ; Complete Clearance Rate = 9 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tuvatexib addresses Actinic Keratosis, Cutaneous T-Cell Lymphoma, Brain Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned matched transaction record(s) under the scope “target-level comparable: HK2 x VDAC1.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: HK2 x VDAC1 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
No matched asset or comparable transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods for preparation of jasmonate compounds”. The milestone feed surfaced a patent-application signal described as “Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses”. The milestone feed surfaced a patent-application signal described as “Stable pharmaceutical compositions for topical administration and uses thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO